215 related articles for article (PubMed ID: 19267255)
1. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
Barnett AH; Millar HL; Loze JY; L'Italien GJ; van Baardewijk M; Knapp M
Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):239-47. PubMed ID: 19267255
[TBL] [Abstract][Full Text] [Related]
2. Predicted risk of diabetes and coronary heart disease in patients with schizophrenia: aripiprazole versus standard of care.
Blonde L; Kan HJ; Gutterman EM; L'Italien GJ; Kim MS; Hanssens L; McQuade RD
J Clin Psychiatry; 2008 May; 69(5):741-8. PubMed ID: 18435564
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
5. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
6. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.
Kerwin R; Millet B; Herman E; Banki CM; Lublin H; Pans M; Hanssens L; L'Italien G; McQuade RD; Beuzen JN
Eur Psychiatry; 2007 Oct; 22(7):433-43. PubMed ID: 17555947
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study.
King D; Knapp M; Thomas P; Razzouk D; Loze JY; Kan HJ; van Baardewijk M
Curr Med Res Opin; 2011 Feb; 27(2):365-74. PubMed ID: 21166610
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole.
Potkin SG; Raoufinia A; Mallikaarjun S; Bricmont P; Peters-Strickland T; Kasper W; Baker RA; Eramo A; Sanchez R; McQuade R
Curr Med Res Opin; 2013 Oct; 29(10):1241-51. PubMed ID: 23822566
[TBL] [Abstract][Full Text] [Related]
9. Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.
Kane JM; Sanchez R; Zhao J; Duca AR; Johnson BR; McQuade RD; Eramo A; Baker RA; Peters-Strickland T
J Med Econ; 2013 Jul; 16(7):917-25. PubMed ID: 23663091
[TBL] [Abstract][Full Text] [Related]
10. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
11. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
13. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults.
Citrome L; Kalsekar I; Baker RA; Hebden T
Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104
[TBL] [Abstract][Full Text] [Related]
14. Practical prescribing with aripiprazole in schizophrenia: consensus recommendations of a UK multidisciplinary panel.
Sullivan G; Bienroth M; Jones M; Millar H; Ratna L; Taylor D
Curr Med Res Opin; 2007 Jul; 23(7):1733-44. PubMed ID: 17588303
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
[TBL] [Abstract][Full Text] [Related]
16. Psychosocial functioning in patients with schizophrenia treated with aripiprazole - an office-based real-world setting. Results from the German post-marketing surveillance study.
Bergmann F; Zacher A; Nass A; Urban R; Werner C; Spevakné-Göröcs T; Kungel M; Ebrecht M; Modell S
Pharmacopsychiatry; 2009 May; 42(3):101-8. PubMed ID: 19452378
[TBL] [Abstract][Full Text] [Related]
17. Aripiprazole and neuroleptic malignant syndrome.
Chakraborty N; Johnston T
Int Clin Psychopharmacol; 2004 Nov; 19(6):351-3. PubMed ID: 15486522
[TBL] [Abstract][Full Text] [Related]
18. Torticollis after low-dose aripiprazole administration in a Thai schizophrenia patient.
Ittasakul P; Srivastava S; Hiranyatheb T; Ketter TA
Asian J Psychiatr; 2012 Dec; 5(4):365-6. PubMed ID: 23174451
[No Abstract] [Full Text] [Related]
19. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
[TBL] [Abstract][Full Text] [Related]
20. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
